Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Biotechnology

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

Phat3479fafag Dec. 6 at 6:54 PM

$SBET $UPST https://www.linkedin.com/posts/kara-frazier-undefined-152b18398_%F0%9D%99%85%F0%9D%99%A4%F0%9D%99%9E%F0%9D%99%A3-%F0%9D%99%A4%F0%9D%99%AA%F0%9D%99%A7-%F0%9D%99%92%F0%9D%99%9D%F0%9D%99%96%F0%9D%99%A9-%F0%9D%99%A8%F0%9D%98%BC%F0%9D%99%A5%F0%9D%99%A5-%F0%9D%99%9C%F0%9D%99%A7%F0%9D%99%A4%F0%9D%99%AA%F0%9D%99%A5-activity-7402682930860408832-j9IJ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAGGyi84BBMDG8iCjbaA6HkNhe-7gJeWuWnc $SGBX $BTAI

0 · Reply

democratsaredisease Dec. 6 at 2:10 AM

$AI $BBAI $BTAI Report this soammer

0 · Reply

FoobarSwopey Dec. 6 at 1:03 AM

$BTAI okay, correct spelling is Que sera, sera

0 · Reply

FoobarSwopey Dec. 6 at 1:02 AM

$BTAI I'm not even going to try to guess on this stock anymore. Ka sura sura!!! Google it if you young ones don't know what that phrase means. 🙂

0 · Reply

PolyesterJacket Dec. 5 at 2:51 PM

$BTAI No more shares available for shorting, per Fidelity. @Boom_Badabing

1 · Reply

av29 Dec. 5 at 7:46 AM

$BTAI Short squeeze on the way?

0 · Reply

av29 Dec. 5 at 7:44 AM

$BTAI Short squeeze on the way?

0 · Reply

tommy45 Dec. 4 at 8:56 PM

$BTAI long term bullish on btai watching cosm oversold looking for a big move up in December. Ctm great company with usa contracts plus no debt gl guys

1 · Reply

idk88 Dec. 4 at 6:27 PM

$BTAI should be soon $20.00

0 · Reply

VIKS4TRADE Dec. 4 at 6:06 PM

$BTAI any update on the class action lawsuit?

1 · Reply

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Nov 12, 2025, 7:00 AM EST - 25 days ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Oct 24, 2025, 11:38 AM EDT - 6 weeks ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 13, 2025, 7:00 AM EDT - 7 weeks ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Sep 18, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 10, 2025, 6:41 PM EDT - 3 months ago

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

Sep 10, 2025, 3:08 PM EDT - 3 months ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 6:30 AM EDT - 3 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 4, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 3 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 3 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:29 AM EDT - 3 months ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 3 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 13, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 7:55 AM EDT - 4 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 6 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 9 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 9 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 9 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 9 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 9:07 AM EST - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

May 28, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 9, 2024, 9:53 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

Phat3479fafag Dec. 6 at 6:54 PM

0 · Reply

democratsaredisease Dec. 6 at 2:10 AM

$AI $BBAI $BTAI Report this soammer

0 · Reply

FoobarSwopey Dec. 6 at 1:03 AM

$BTAI okay, correct spelling is Que sera, sera

0 · Reply

FoobarSwopey Dec. 6 at 1:02 AM

$BTAI I'm not even going to try to guess on this stock anymore. Ka sura sura!!! Google it if you young ones don't know what that phrase means. 🙂

0 · Reply

PolyesterJacket Dec. 5 at 2:51 PM

$BTAI No more shares available for shorting, per Fidelity. @Boom_Badabing

1 · Reply

av29 Dec. 5 at 7:46 AM

$BTAI Short squeeze on the way?

0 · Reply

av29 Dec. 5 at 7:44 AM

$BTAI Short squeeze on the way?

0 · Reply

tommy45 Dec. 4 at 8:56 PM

$BTAI long term bullish on btai watching cosm oversold looking for a big move up in December. Ctm great company with usa contracts plus no debt gl guys

1 · Reply

idk88 Dec. 4 at 6:27 PM

$BTAI should be soon $20.00

0 · Reply

VIKS4TRADE Dec. 4 at 6:06 PM

$BTAI any update on the class action lawsuit?

1 · Reply

Just_An_Investor Dec. 4 at 4:00 PM

$BTAI Once again I think this bounce back is based on broader market trends. I expect a settling around $1.85-$1.90 once things calm down. Be bullish for the long term and because you believe in the company. Don't buy in based on day to day market trends.

0 · Reply

11thestate Dec. 4 at 3:30 PM

With all the buzz around $BTAI lately, here’s something worth noting: BioXcel is already facing an investor lawsuit — covering multiple allegations. We’re not making predictions, but it’s worth a look. Always good to know the full context. https://11th.com/cases/bioxcel-investor-lawsuit

2 · Reply

MakeM0ney_444 Dec. 4 at 3:25 PM

$BTAI apparently not

0 · Reply

HedgeAlerts Dec. 4 at 6:34 AM

Hedge Alert Live - Protect Your Portfolio Contract: $BTAI $1.50 Put · JAN 16, 2026 Exp Entry Price: $0.75 - $4.50 Exit Price Target: $1.65 Profit Margin: +120% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

av29 Dec. 3 at 8:48 PM

$BTAI Let's hope you focus above the average of 20

0 · Reply

av29 Dec. 3 at 8:47 PM

$BTAI Hope to see it soon for $5

0 · Reply

av29 Dec. 3 at 8:46 PM

$BTAI What's happening with this stock that's already flying high?

0 · Reply

FoobarSwopey Dec. 3 at 7:48 PM

$BTAI Good Lord tommy45...I lost track of your share count... guessing you are well over 100k shares?

1 · Reply

MetalFistSlip Dec. 3 at 7:37 PM

$BTAI Up 11% since this Bears post lol

0 · Reply

tommy45 Dec. 3 at 7:26 PM

$BTAI added another 5k here long term bullish into 2026 for sure. watching CTM and COSM for a BIG run in DEC gl

0 · Reply

tommy45 Dec. 3 at 4:37 PM

$BTAI long term bullish here watching ctm and cosm for a run up in price in dec gl.

0 · Reply

PolyesterJacket Dec. 3 at 4:08 PM

$BTAI Fidelity is telling me there are only 744 shares available for shorting. Somebody buy those please, to put an end to this.

1 · Reply

Market Cap	45.27M
Revenue (ttm)	2.27M
Net Income (ttm)	-59.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,625.55%
Debt to Equity Ratio	-1.23

Volume	267,700
Avg Vol	847,820
Day's Range	N/A - N/A
Shares Out	21.87M
Stochastic %K	49%
Beta	0.21
Analysts	Sell
Price Target	$9.67